Ortho Startup OSSO Raises ₹4 Cr Seed Funding from Haldiram Family

HEALTHCAREBIOTECH

Overview

Healthcare startup OSSO, specializing in regenerative orthopaedics, has secured INR 4 crore in seed funding from the Haldiram family office. The capital will fuel network expansion, introduce nanoscopy to India, and bolster non-surgical treatment options. This growth aligns with rising sports injuries and an aging population seeking alternatives to traditional surgeries.

OSSO Secures Seed Capital

Healthcare startup OSSO, a specialist in regenerative orthopaedics, has raised INR 4 crore ($443K) in a seed funding round. The investment was led by the prominent Haldiram family office, signaling robust backing for the company's innovative approach to bone and joint health. Several angel investors also participated, including key figures from the Jindal Group and Culture Cap.

Expansion and Technological Advancements

The newly acquired capital is designated for scaling OSSO's network of treatment centers, with plans to launch three new locations in Gurugram by year-end. A significant focus will be on introducing nanoscopy to the Indian market, a sophisticated diagnostic technique not yet in routine clinical practice. This move aims to enhance the startup's offerings in regenerative orthopaedics, providing alternatives to traditional surgical interventions.

Market Tailwinds

Founded in 2024, OSSO targets a growing demand for specialized orthopaedic care, driven by increased youth participation in sports and a rising elderly population dealing with bone-related disorders. The company has already provided treatment to over 1,000 patients for conditions such as arthritis and sports-related ligament injuries. This expansion taps into a market segment experiencing a significant surge in demand, highlighted by a reported 400% rise in ACL injuries over the past decade.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.